Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
New England Journal of Medicine · 18.09.2025 · 393 (11) · 1065-1076
DOI: 10.1056/nejmoa2505669 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 18.09.2025. Verfasst von Julio Rosenstock und 12 weiteren Autor:innen. Beteiligte Einrichtung: Velocity Clinical Research Center at Medical City Dallas, Dallas. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycemic Control. Die Arbeit wurde bisher 140-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with diet and exercise, a glycated hemoglobin level of at least 7.0% but no more than 9.5%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 23.0. The primary end point was the change from baseline to week 40 in the glycated hemoglobin level. A key secondary end point was the percent change in body weight from baseline to week 40. RESULTS: A total of 559 participants underwent randomization. The mean glycated hemoglobin level at baseline was 8.0%. At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo. All three doses of orforglipron were superior to placebo with respect to the primary end point; the estimated mean difference from placebo was -0.83 percentage points (95% confidence interval [CI], -1.10 to -0.56) with the 3-mg dose, -1.06 percentage points (95% CI, -1.33 to -0.79) with the 12-mg dose, and -1.07 percentage points (95% CI, -1.33 to -0.81) with the 36-mg dose (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Velocity Clinical Research Center at Medical City Dallas, Dallas.
- Velocity Clinical Research, Huntington Park, CA.
- Hospital Angeles Chihuahua, Chihuahua, Mexico.
- Eli Lilly, Indianapolis.
ORCID-Profile: Julio Rosenstock
Förderung
- Eli Lilly and Company
Zitieren
APA
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W. S., Liu, R., Li, J., Fernández Landó, L., Denning, M., Ludwig, L., Chen, Y., & ACHIEVE-1 Trial Investigators (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine, 393(11), 1065-1076. https://doi.org/10.1056/nejmoa2505669
Vancouver
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine. 2025;393(11):1065-1076. doi:10.1056/nejmoa2505669
BibTeX
@article{Rosenstock2025,
author = {Rosenstock, Julio and Hsia, Stanley and Nevarez Ruiz, Luis and Eyde, Sarah and Cox, David and Wu, Wen-Shuo and Liu, Rong and Li, Jianghao and Fernández Landó, Laura and Denning, Max and Ludwig, Lisa and Chen, Yanyun and ACHIEVE-1 Trial Investigators, ACHIEVE-1 Trial Investigators},
title = {Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {11},
pages = {1065--1076},
doi = {10.1056/nejmoa2505669}
}
EUVIMED